Maxillofacial Plastic and Reconstructive Surgery

  • 제38권
  • /
  • Pages.6.1-6.8
  • /
  • 2016
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
대한악안면성형재건외과학회 (Korean Association of Maxillofacial Plastic and Reconstructive Surgeons)
권호 표지
DOI QR코드

DOI QR Code

Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases

  • Kim, Hong-Joon (Department of Oral and Maxillofacial Surgery, College of Medicine, University of Ulsan, Seoul Asan Medical Center) ;
  • Park, Tae-Jun (Department of Oral and Maxillofacial Surgery, College of Medicine, University of Ulsan, Seoul Asan Medical Center) ;
  • Ahn, Kang-Min (Department of Oral and Maxillofacial Surgery, College of Medicine, University of Ulsan, Seoul Asan Medical Center)
  • 투고 : 2015.11.01
  • 심사 : 2016.01.21
  • 발행 : 2016.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Intravenous bisphosphonates have been used in metastatic breast cancer patients to reduce pathologic bone fracture and bone pain. However, necrosis of the jaw has been reported in those who received intravenous bisphosphonates. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is caused by dental extraction, dental implant surgery, and denture wearing; however, it occurs spontaneously. The purpose of this study was to report BRONJ in metastatic breast cancer patients. Methods: Consecutive 25 female patients were referred from the Department of Oncology from 2008 to 2014 for jaw bone discomfort. Staging of breast cancer, history of bisphosphonate infusion, etiology of BRONJ, and treatment results were reviewed. Average age of the patients was 55.4 years old (38-74). Twelve maxillae and 16 mandibles were involved. Conservative treatments such as irrigation, antibiotic medication, analgesics, and oral gargle were applied for all patients for the initial treatment. Patients who had sequestrum underwent debridement and primary closure. Results: The etiologies of BRONJ were dental extraction (19 cases), dental implant (2 cases), and endodontic treatment (1 case). However, three patients did not have any risk factors to cause BRONJ. Three patients died of progression of metastasis during follow-up periods. Surgical debridement was performed in 21 patients with success in 18 patients. Three patients showed recurred bone exposure and infection after operation. Conclusions: Prevention of the BRONJ is critical in metastatic breast cancer patients. Conservative treatment to reduce pain, discomfort, and infection is recommended for the initial therapy. However, if there is a sequestrum, surgical debridement and primary closure is the key to treat the BRONJ.

키워드

참고문헌

  1. Ito H, Matsuo K (2016) Molecular epidemiology, and possible real-world applications in breast cancer. Breast Cancer 23:33-8 https://doi.org/10.1007/s12282-015-0609-8
  2. Bundred N (2012) Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 38:776-86 https://doi.org/10.1016/j.ctrv.2012.02.002
  3. Piccioli A (2015) Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Eur J Orthop Surg Traumatol 25:29-37
  4. Gnant M, Dubsky P, Hadji P (2012) Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 192:65-91
  5. Ahn KM (2014) Chapter 8. Bisphosphonate related osteonecrosis of the jaw in multiple myeloma. Multiple myeloma: risk factors, diagnosis and treatments. Nova Science publishers, Inc., New York
  6. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-34 https://doi.org/10.1016/j.joms.2004.02.004
  7. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-9 https://doi.org/10.1016/S1470-2045(08)70204-3
  8. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-57 https://doi.org/10.1200/JCO.2003.08.017
  9. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-6 https://doi.org/10.1172/JCI118722
  10. Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930-5 https://doi.org/10.1172/JCI114100
  11. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-87
  12. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-11 https://doi.org/10.1172/JCI116422
  13. Shannon J, Shannon J, Modelevsky S, Grippo AA (2011) Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 59:2350-5 https://doi.org/10.1111/j.1532-5415.2011.03713.x
  14. Body JJ (2003) Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97:859-65 https://doi.org/10.1002/cncr.11139
  15. Berenson JR (2005) Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10:52-62 https://doi.org/10.1634/theoncologist.10-1-52
  16. Coleman RE (2000) Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast Cancer 7:361-9 https://doi.org/10.1007/BF02966406
  17. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-7 https://doi.org/10.1016/S0278-2391(03)00720-1
  18. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938-56 https://doi.org/10.1016/j.joms.2014.04.031
  19. Kourie HR, Antoun J, El Rassy E, Rassy M, Sader-Ghorra C, Kattan J (2015) Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: a literature review. J Bone Oncol 4:77-9 https://doi.org/10.1016/j.jbo.2015.09.001
  20. Matsuo A, Hamada H, Takahashi H, Okamoto A, Kaise H, Chikazu D (2015) Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients. Odontology. [Epub ahead of print]
  21. Pilanci KN, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z et al (2015) Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? Medicine (Baltimore) 94:e671 https://doi.org/10.1097/MD.0000000000000671
  22. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A (2010) American Joint Committee on Cancer, editors. AJCC cancer staging manual, 7th edn. Springer, New York, NY
  23. Nomura T, Shibahara T, Uchiyama T, Yamamoto N, Shibui T, Yakushiji T et al (2013) Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. Bull Tokyo Dent Coll 54:117-25 https://doi.org/10.2209/tdcpublication.54.117
  24. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-36 https://doi.org/10.1359/jbmr.080205
  25. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-61 https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  26. Drake MT, Cremers SC (2010) Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv 10:141-52 https://doi.org/10.1124/mi.10.3.5
  27. Holzinger D, Seemann R, Klug C, Ewers R, Millesi G, Baumann A et al (2013) Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol 49:66-70 https://doi.org/10.1016/j.oraloncology.2012.07.008
  28. Eid A, Atlas J (2014) The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. Oral Maxillofac Surg Clin North Am 26:231-7 https://doi.org/10.1016/j.coms.2014.01.009
  29. Jacobsen C, Zemann W, Obwegeser JA, Gratz KW, Metzler P (2014) The phosphorous necrosis of the jaws and what can we learn from the past: a comparison of "phossy" and "bisphossy" jaw. Oral Maxillofac Surg 18:31-7 https://doi.org/10.1007/s10006-012-0376-z
  30. Rayman S, Almas K, Dincer E (2009) Bisphosphonate-related jaw necrosis: a team approach management and prevention. Int J Dent Hyg 7:90-5 https://doi.org/10.1111/j.1601-5037.2008.00331.x
  31. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-20
  32. Jang HW, Kim JW, Cha IH (2015) Development of animal model for bisphosphonates-related osteonecrosis of the jaw (BRONJ). Maxillofac Plast Reconstr Surg 37:18 https://doi.org/10.1186/s40902-015-0020-6
  33. Tam Y, Kar K, Nowzari H, Cha HS, Ahn KM (2014) Osteonecrosis of the jaw after implant surgery in patients treated with bisphosphonates-a presentation of six consecutive cases. Clin Implant Dent Relat Res 16:751-61 https://doi.org/10.1111/cid.12048
  34. Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM et al (2012) Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J Oral Maxillofac Surg 70:2501-7 https://doi.org/10.1016/j.joms.2012.05.019
  35. Jang-Ha Lee M-KK, Kim S-G, Park Y-W, Park S-W, Park Y-J (2013) Surgical management of bisphosphonate related osteonecrosis of the jaw using pedicled buccal fat pad flap. J Korean Assoc Maxillofac Plast Reconstr Surg 35:174-7
  36. Ho Kyung Lee MHS, Pang KM, Song SI, Lee JK (2013) Comparative study on surgical and conservative management of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in disease stage 2. J Korean Assoc Maxillofac Plast Reconstr Surg 35:302-9
  37. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860-7 https://doi.org/10.1002/cncr.22991

피인용 문헌

  1. Uncommon presentation of potential medication-related osteonecrosis of the jaw vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-1902-5
  2. Overall and disease-specific survival outcomes following primary surgery for oral squamous cell carcinoma: analysis of consecutive 67 patients vol.45, pp.2, 2019, https://doi.org/10.5125/jkaoms.2019.45.2.83